Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00219
|
|||||
| Drug Name |
Idelalisib
|
|||||
| Synonyms |
(S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 1146702-54-6; 5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; AK145603; CAL 101; CAL-101; CAL-101 (Idelalisib, GS-1101); CAL101; CHEBI:82701; CHEMBL2216870; GS-1101; Idelalisib; UNII-YG57I8T5M0; YG57I8T5M0; Zydelig
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Chronic lymphocytic leukemia [ICD11: 2A82.0] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H18FN7O
|
|||||
| Canonical SMILES |
CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
|
|||||
| InChI |
InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1
|
|||||
| InChIKey |
IFSDAJWBUCMOAH-HNNXBMFYSA-N
|
|||||
| CAS Number |
CAS 870281-82-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 415.4 | Topological Polar Surface Area | 99.2 | ||
| Heavy Atom Count | 31 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
3.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
124360767
, 124757878
, 125164680
, 135294860
, 136023431
, 136340110
, 136350004
, 136367521
, 136368015
, 137275917
, 141870606
, 144115773
, 152258425
, 160647261
, 160778577
, 162011391
, 162038002
, 162202617
, 163315619
, 163352092
, 163642790
, 163908064
, 164043527
, 164193919
, 16728852
, 170497648
, 170501514
, 172650954
, 172913174
, 174531110
, 177749172
, 178103352
, 184826685
, 198954688
, 198994003
, 215785737
, 223447422
, 223471406
, 223573729
, 223705059
, 224220340
, 225144930
, 226689936
, 248327652
, 249737291
, 249814532
, 249828711
, 250183703
, 250220450
, 78058152
|
|||||
| ChEBI ID |
ChEBI:82701
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | Idelalisib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB09054) | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.